DelveInsight’s, “Bladder Cancer Pipeline Insight 2023” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in the Bladder cancer pipeline landscape. It covers the Bladder Cancer pipeline drug profiles, including Bladder Cancer clinical trials and nonclinical stage products. It also covers the Bladder Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Bladder Cancer pipeline products in this space.
In the Bladder Cancer pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, Bladder Cancer clinical trial studies, Bladder Cancer NDA approvals (if any), and product development activities comprising the technology, Bladder cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Key takeaways from the Bladder Cancer Pipeline Report
To explore more information on the latest breakthroughs in the Bladder Cancer treatment landscape of the report, click here @ Bladder Cancer Pipeline Outlook
Recent Breakthroughs from the Bladder Cancer Treatment Landscape
Bladder Cancer Overview
Bladder cancer usually starts in the cells that line the inside of the bladder. It typically affects adults over the age of 70 and is more common in men. Bladder cancer is the fifth most prevalent type of cancer in the general population and the fourth most common in males. When detected early, bladder cancer usually responds well to bladder cancer treatment. Smoking is among the most common bladder cancer causes. Blood in the urine is usually the first sign of bladder cancer. Other bladder cancer symptoms may include urine pain or burning, as well as a change in urinary habits. This can include frequent urination or the need to urinate but being unable to do so. The tests used for bladder cancer diagnosis include biopsy, cystoscopy, urine cytology, imaging tests, and others.
Request a sample and discover the recent advances in Bladder Cancer Ongoing Clinical Trial Analysis and Medications, click here @ Bladder Cancer Treatment Landscape
Bladder cancer Emerging Drugs
CG0070: CG Oncology
CG0070 is an investigational oncolytic immunotherapy based on a modified common cold adenovirus backbone that contains a cancer-specific promoter and a GM-CSF transgene. CG0070 was designed to work in two important and complementary ways. First, it replicates inside the tumor’s cells causing tumor cell lysis and immunogenic cell death. Then, the rupture of the cancer cells can release tumor-derived antigens, along with GM-CSF, that can stimulate a systemic anti-tumor immune response that involves the body’s own white blood cells. The scientific rationale and clinical profile of CG0070 make it an ideal agent to be developed for a variety of solid tumor types to be used alone or in combination with immune checkpoint modulators.
N-803: ImmunityBio
The cytokine interleukin-15 (IL-15) plays a crucial role in the immune system by affecting the development, maintenance, and function of the natural killer (NK) and T cells. N-803 is a novel IL-15 superagonist complex consisting of an IL-15 mutant (IL-15N72D) bound to an IL-15 receptor α/IgG1 Fc fusion protein. Its mechanism of action is direct specific stimulation of CD8+ T cells and NK cells through beta gamma T-cell receptor binding (not alpha) while avoiding T-reg stimulation. N-803 has improved pharmacokinetic properties, longer persistence in lymphoid tissues and enhanced anti-tumor activity compared to native, non-complexed IL-15 in vivo. N-803 is currently being evaluated for adult patients in two clinical NMIBC trials. QUILT 2005 is investigating use of N-803 in combination with BCG for patients with BCG-naïve NMIBC; QUILT 3032 is studying N-803 in combination with BCG in patients with BCG-unresponsive NMIBC CIS and Papillary Disease. In May 2022, ImmunityBio, Inc. announced it had submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for N-803, a first-in-class IL-15 superagonist, plus Bacillus Calmette-Guérin (BCG) for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS) with or without Ta or T1 disease.
UGN-102: UroGen
UroGen is developing UGN-102 (mitomycin) for intravesical solution as a primary nonsurgical alternative to repetitive TURBT. UGN-102 is an investigational formulation that utilizes our innovative technology, RTGel™ reverse-thermal hydrogel, for the treatment of low-grade NMIBC. Instilled via standard catheters, UGN-102 is designed to dwell for a period of several hours before being excreted via normal urine flow.
Trilaciclib: G1 Therapeutics
Trilaciclib, an IV-administered transient CDK4/6 inhibitor, is a first-in-class therapy designed to preserve bone marrow and immune system function during chemotherapy to improve patient outcomes. The company is currently enrolling patients in PRESERVE 3, Phase 2, randomized, open-label study of trilaciclib administered with first-line platinum-based chemotherapy and the immune checkpoint inhibitor avelumab maintenance therapy in patients with untreated, locally advanced or metastatic urothelial carcinoma (mUC). Myeloprotection and anti-tumor efficacy endpoints are being assessed in this study.
Bladder Cancer Therapeutics Assessment
There are approx. 100+ key companies which are developing the therapies for Bladder cancer. The companies which have their Bladder cancer drug candidates in the most advanced stage, i.e. phase III include, CG Oncology.
For further information, refer to the detailed Bladder Cancer Unmet Needs, Bladder Cancer Market Drivers, and Bladder Cancer Market Barriers, click here @ Bladder Cancer Ongoing Clinical Trial Analysis
Scope of the Bladder Cancer Pipeline Report
Table of Content
1. Introduction
2. Bladder cancer Executive Summary
3. Bladder cancer: Overview
4. Bladder cancer Pipeline Therapeutics
5. Bladder cancer Therapeutic Assessment
6. Bladder cancer – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. CG0070: CG Oncology
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Trilaciclib: G1 Therapeutics
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. MV-NIS: Vyriad
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. FEP 633: PRISM BioLab
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Bladder cancer Key Companies
21. Bladder cancer Key Products
22. Bladder cancer- Unmet Needs
23. Bladder cancer- Market Drivers and Barriers
24. Bladder cancer- Future Perspectives and Conclusion
25. Bladder cancer Analyst Views
26. Bladder cancer Key Companies
27. Appendix
Dive deep into rich insights for drugs for Bladder Cancer Market Drivers and Bladder Cancer Market Barriers, click here @ Bladder cancer Unmet Needs and Analyst Views
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/report-store/stem-cell-market